IP Library Granted Patent US 9,683,049
Granted Patent B2
US 9,683,049 · App. 14/250,250 · Granted Jun 20, 2017

Modulation of TIM receptor activity in combination with cytoreductive therapy

Inventors: Jennifer Jones (Palo Alto, CA); Rosemarie Dekruyff (Newton, MA); Dale T. Umetsu (Newton, MA); Gordon J. Freeman (Boston, MA); Susan Jane Knox (Stanford, CA)
Assignees: The Board of Trustees of the Leland Stanford Junior University; Dana-Farber Cancer Institute, Inc.; Children's Medical Center Corporation
C07K16/30A61K39/0011C07K14/70503C07K2317/75
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,683,049
App. No.
14/250,250
Granted
Jun 20, 2017
Kind
B2
Abstract

A genetic locus and corresponding family of proteins associated with regulation of immune function and cell survival are provided. These genes encode cell surface molecules with conserved IgV and mucin domains. The locus comprising the TIM family is genetically associated with immune dysfunction, including asthma. Furthermore, the TIM gene family is located within a region of human chromosome 5 that is commonly deleted in malignancies and myelodysplastic syndrome. Polymorphisms in the gene sequences are associated with the development of airway hyperreactivity and allergic inflammation, and T cell production of IL-4 and IL-13. The proteins include the human hepatitis A cellular receptor, hHAVcr-1.

Claims (6)

1. A method for the treatment of cancer in an individual, the method comprising:

administering to said individual an agonistic antibody that specifically binds to TIM1.

2. The method of claim 1 , wherein the cancer is breast cancer.

3. The method of claim 2 , wherein the cancer is metastatic breast cancer.

4. The method of claim 1 , further administering in combination with the agonistic antibody that binds to TIM1, an effective dose of a cytoreductive agent.

5. The method according to claim 1 , wherein said antibody is an agonist of TIM-1 and potentiates the effect of chemotherapeutic agents or radiation therapy.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2016
From: THE CHILDREN'S HOSPITAL CORPORATION
To: CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 039060/0927 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 7, 2014
From: JONES, JENNIFER; KNOX, SUSAN JANE
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 033490/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 7, 2014
From: DEKRUYFF, ROSEMARIE; UMETSU, DALE T.
To: CHILDREN'S HOSPITAL CORPORATION
Reel/Frame 033490/0715 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 7, 2014
From: FREEMAN, GORDON J.
To: DANA-FARBER CANCER INSTITUTE, INC.
Reel/Frame 033490/0743 →
Continuity (5)
Continuation 13176651 · Jul 5, 2011
Continuation In Part 12485765 · Jun 16, 2009
Continuation 10188012 · Jul 1, 2002
Provisional Application 60302344 · Jun 29, 2001
Related Publication 20150023986A1 · Jan 22, 2015